Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have received a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $29.14.

Several analysts have recently weighed in on BCYC shares. B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $33.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. JMP Securities cut their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $15.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $8.85 on Wednesday. Bicycle Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $28.67. The company’s 50 day simple moving average is $11.74 and its 200 day simple moving average is $17.91. The firm has a market capitalization of $612.44 million, a price-to-earnings ratio of -2.69 and a beta of 1.12.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. During the same period last year, the business posted ($1.16) EPS. Bicycle Therapeutics’s revenue was down 30.2% on a year-over-year basis. As a group, analysts predict that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the transaction, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at $482,190. The trade was a 7.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Santiago Arroyo sold 4,943 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the transaction, the insider now directly owns 69,057 shares of the company’s stock, valued at $973,013.13. This trade represents a 6.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Several large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. grew its holdings in Bicycle Therapeutics by 406.2% during the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company’s stock valued at $63,769,000 after buying an additional 3,655,101 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Bicycle Therapeutics by 43.3% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,236 shares of the company’s stock valued at $1,123,000 after purchasing an additional 24,260 shares during the last quarter. Millennium Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter worth $2,475,000. Fcpm Iii Services B.V. increased its position in Bicycle Therapeutics by 47.5% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock valued at $48,333,000 after acquiring an additional 1,112,369 shares during the period. Finally, Caption Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter worth about $2,283,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.